Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + gemcitabine + cisplatin
- Development stage
- Phase 3
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Camrelizumab + gemcitabine + cisplatin is a combination therapy consisting of an anti-PD-1 antibody (camrelizumab) with two chemotherapy agents (gemcitabine and cisplatin). This combination has shown significant efficacy in the treatment of recurrent or metastatic nasopharyngeal carcinoma. The CAPTAIN-1st phase 3 trial demonstrated that adding camrelizumab to gemcitabine and cisplatin significantly improved progression-free survival compared to gemcitabine and cisplatin alone, with a manageable safety profile. The combination works through immune checkpoint inhibition (camrelizumab) alongside the cytotoxic effects of traditional chemotherapy (gemcitabine and cisplatin).
- Other names
- camrelizumab plus gemcitabine and cisplatincamrelizumab plus GP
02
Targets
DNADNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + gemcitabine + cisplatin.